Exact Sciences with steady analyst picture, shares trade on NASDAQ
Published on 06/30/2026 at 10:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-30, 10:11.
Exact Sciences (US30063P1057) begins this Tuesday with a stable analyst backdrop and continued listing on the NASDAQ in New York. The stock remains linked to expectations for upcoming quarterly figures and the broader diagnostics peer group on the U.S. market.
How analysts view Exact Sciences
Broker and data-platform consensus typically shows a mixed but broadly constructive stance on Exact Sciences, with a spread from Buy to Hold ratings and only a minority of analysts on Sell. Several houses track the stock in the U.S. healthcare and diagnostics segment with 12-month price targets in circulation.
Aggregators such as MarketScreener or TipRanks usually cite more than ten covering analysts for Exact Sciences, combining large international houses and regional brokers. Rating language ranges from "outperform" to "neutral" depending on the assumed growth trajectory in cancer screening and molecular diagnostics.
The calendar and earnings focus
Exact Sciences reports its financials on a U.S. quarterly rhythm, and investors watch the next scheduled update closely for guidance on revenue growth and profitability. The firm traditionally publishes results and holds a conference call after the U.S. market close on NASDAQ days.
Consensus estimates from typical data providers cover revenue, adjusted EBITDA or operating loss, and sometimes cash burn metrics for the coming quarters. Deviations from these expectations in prior reports have influenced short-term share moves on NASDAQ around the earnings dates.
Background and price data on Exact Sciences
For more information on the Exact Sciences shares, including past earnings dates and price history, see the detailed overview on ad-hoc-news.de and the company’s own Investor Relations page.
How the company makes its money
Exact Sciences generates revenue primarily from molecular diagnostic tests with a focus on cancer detection. A central product is the Cologuard stool DNA screening test for colorectal cancer, which is marketed in the U.S. as a non-invasive alternative to colonoscopy and reimbursed by many insurers.
Where the shares trade today
The Exact Sciences shares (US30063P1057) trade on 2026-06-30, 10:11 on the NASDAQ in U.S. dollars. At the time of writing, the latest intraday price and market capitalization are based on the live data feed of the U.S. exchange.
Key data on the Exact Sciences shares
- Company: Exact Sciences Corp.
- ISIN: US30063P1057
- WKN: A1W9DE
- Ticker: EXAS
- Trading venue: NASDAQ
- Price (as of 2026-06-30, 10:11): [latest intraday] USD
- Market cap: [latest figure] USD (as of 2026-06-30)
- Sector / industry: Health Care, Diagnostics & Research
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data and assessments may change; investors should consult multiple sources and, where appropriate, professional advisors before making investment decisions.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
